Skip to main content
Search

Memorial Sloan Kettering Cancer Center

7 related articles

Subscribe to updates
  1. arXiv

    Compute only where the signal is: Conformal Adaptation certifies sparse inference, holding Dice close on brain-tumor segmentation

    Medical and astronomical images are orders of magnitude larger than natural images, yet tumors and galaxies occupy a tiny fraction of the data, and uniform compression such as quantization or pruning can erode precision exactly there. Conformal Adaptation first screens candidates with a low-resolution model, calibrates the selection threshold with conformal risk control so the discarded cells carry at most a user-set expected fraction of true signal mass, then refines only the selected regions. Across brain-tumor segmentation, head-and-neck segmentation, calcium spike-rate inference and galaxy flux super-resolution, the pipeline cuts computation while keeping accuracy close, and VISTA3D reaches an 82.10x FLOPs speedup in CPU-only inference.

  2. bioRxiv

    HERACLES skips the tree search: quartet likelihoods rebuild a 150,000-cell lineage in about four hours on one GPU

    CRISPR lineage recorders can trace the ancestry of hundreds of thousands of cells, but likelihood-based tree building searches over tree topologies and becomes impractical at that scale. HERACLES places each cell as a point in hyperbolic space, scores the CRISPR editing likelihood of sampled cell quartets, and optimizes those coordinates by gradient descent before a single neighbour-joining pass yields the full tree. On simulated benchmarks its reconstruction error is lower than LAML, Startle-NNI and distance-based methods, and it handles 150,000 cells in about four hours on one GPU.

  3. medRxiv

    Cancer side effects can be forecast from routine labs: SPARC holds up across 11 hospitals

    Predicting cancer treatment side effects has long relied on static nomograms built from a handful of variables. SPARC instead models longitudinal sequences of blood counts, metabolic panels and vital signs, pretraining on 101,920,379 measurements from 224,047 patients and then fine-tuning for mortality, anemia, neutropenia, febrile neutropenia, acute kidney injury and liver toxicity. It matched or led comparison models on held-out, prospective and multi-hospital cohorts, and its predicted risk strata identified patients most likely to benefit from G-CSF prophylaxis.

  4. A single-cell velocity model you can perturb: it named three rescue targets for Arid1a-loss B cells, and mice confirmed all three

    DynaVelo puts RNA expression and transcription-factor motif accessibility from single-cell multiome data into one neural differential equation, learning a velocity field that can be perturbed rather than only drawn. In wild-type mouse germinal center B cells it recovers dark-zone cycling, the switch to the light zone and recycling; in Arid1a-heterozygous cells it nominated Ctcf, Stat3 and Bcl6 as rescue targets, and all three double-heterozygous mouse strains restored the dark-zone phenotype.

  5. Nature

    Brown fat tracks with fewer heart and psychiatric diagnoses in 101,243 patients, and AI pinpoints the axillary depot

    Among 101,243 patients at a cancer center, those with brown fat had fewer cardiovascular and psychiatric diagnoses; machine learning quantified brown fat activity in about 8,700 people, showing higher activity, especially in the axillary depot, tracked with lower odds of type 2 diabetes and coronary disease, and led to losartan as an activator in mice.

  6. Cancer

    CIBMTR real-world data: about one-third of multiple myeloma patients receiving cilta-cel are frail, with 12-month PFS of 62.7% and OS of 72.8% and doubled ICANS risk

    Using Center for International Blood and Marrow Transplant Research registry data, this study evaluated 541 patients with relapsed/refractory multiple myeloma who received commercial cilta-cel between March 2022 and December 2023 and found that 183 (33.8%) were frail by an adapted simplified frailty score; overall response rates were comparable (82.8% vs. 88.5%), but frail patients had worse 12-month progression-free survival (62.7% vs. 75.9%) and overall survival (72.8% vs. 90.4%) and more any-grade ICANS (32.2% vs. 17.6%), with frailty independently predicting worse PFS (HR 1.67), OS (HR 2.46), and any-grade ICANS (OR 2.01) on multivariable analysis.

  7. Amazon Science

    Designing and Characterizing Antibodies with AI: Three Efforts Spanning Epitope Selection, Affinity Ranking, and Developability Prediction

    This article presents three efforts from Amazon Bio Discovery: MochiBind, a sequence-only predictor that reframes binding affinity as pairwise comparison aggregated by TrueSkill into a global ranking, achieving higher pairwise accuracy than every structure-based baseline on four held-out antigens and scoring 200,000 antibody pairs in roughly 13 seconds on a CPU; CA-MAP, a context-aware multi-property predictor that uses example antibodies in the prompt to absorb batch offsets, holding a 0.99 correlation under a simulated batch effect where standard fine-tuning falls to 0.

You’re all caught up